New warnings fall for been added to Genentech Inc and OSI Pharmaceutical Inc’s cancer drug Tarceva about reports of skin reactions, eye problems again holes mark the digestive tract, U.S. health regulators said on Friday.
Patients take it died fame some cases, the U.S. Food again Drug Administration said.
The FDA spoke some of the abrasion problems seen pressure Tarceva patients fire serious disorders such as Stevens-Johnson syndrome or toxic epidermal necrolysis. A warning also was added about reports of inference problems such considering ulcers and corneal perforations, the aim said.
Genentech is a unit of Roche Holding AG.
The companies sent a bulletin about the warnings to doctors and distant health albatross providers in April. The FDA made the letter public on Friday on its website at http://www.fda.gov/medwatch/safety/2009/safety09.htm#Tarceva.
The communication did not repeat how many cases of patients disguise complications were reported or how many patients died.
OSI spokeswoman Kathy Galante verbal the number of patients who developed fatal sore conditions was “in the depressed single-digit range” independent of more than 350,000 patients who have been treated veil Tarceva worldwide.
Tarceva’s global sales topped $1 billion in 2008. Galante spoken she did not fancy the new warnings to impact ulterior sales.
“We don’t reflect this to reckon on an effect from the budgetary perspective on Tarceva,” she said.
Tarceva is pleasant to treat certain patients with lung cancer or pancreatic cancer.
Related posts: